EQT makes $2.8 billion bid for drugmaker Recipharm

EQT makes $2.8 billion bid for drugmaker Recipharm

Buyout group EQT on Monday announced a cash offer for Swedish contract pharmaceutical maker Recipharm, valuing the company at $2.80 billion. Recipharm, a contract development and manufacturing organisation (CDMO) for the pharma industry, recently signed a preliminary...
AstraZeneca to buy Alexion for $39 billion to expand in immunology

AstraZeneca to buy Alexion for $39 billion to expand in immunology

Britain’s AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away from its fast-growing cancer business in a bet on rare-disease and immunology drugs. The deal comes in a week that AstraZeneca...